Results 81 to 90 of about 14,165 (152)

Palbociclib in Combination with Endocrine Therapy in Patients with Metastatic Breast Cancer in a Real-World Population: Impact of Dose-Intensity, Dose Reductions and Cycle Delays on Efficacy. [PDF]

Curr Oncol
Coussirou J, Grenier J, Mege A, Arnaud A, De Crozals F, Bonnet E, Vazquez L.   +6 more
europepmc   +1 more source

Targeting cell cycle in leukemia: "Is palbociclib the game-changer?": A review. [PDF]

Medicine (Baltimore)
Azizan MA, Abeden Z, Shamsuddin NHN, Ahid F, Mohd Yusoff N, Ismail MN, Ng SK, Isa A.   +7 more
europepmc   +1 more source

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study). [PDF]

Breast Cancer
Nagai SE, Hattori M, Yoshinami T, Masuda H, Okamura T, Watanabe K, Nakayama T, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Sasada S, Ishida T, Futamura M, Muramatsu Y, Kosaka N, Masuda N.   +22 more
europepmc   +1 more source

Dual CDK4/6-PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma. [PDF]

Neoplasia
Barghi F, Saadatzadeh MR, Dobrota EA, Shannon HE, Bailey BJ, Young C, Malko R, Justice R, Riyahi N, Davis C, Bijangi-Vishehsaraei K, Kreklau K, Stevens LK, Koenig J, Sulayman S, Liu S, Wan J, Trowbridge MA, Coy K, Kennedy FM, Sinn AL, Just M, Jackson KW, Sandusky G, Wurtz LD, Collier CD, Mitchell D, Seiden EE, Greenfield EM, Doud E, Mosley A, Angus SP, Ferguson MJ, Pandya PH, Pollok KE.   +34 more
europepmc   +1 more source

Integration of pre‑existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer. [PDF]

Ther Adv Drug Saf
Park C, Kim K, Abifaraj NB, Bryant SD, Heo JH.   +4 more
europepmc   +1 more source

Biomarkers of primary and secondary resistance to cyclin dependent kinases 4 and 6 inhibitors in metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a narrative review. [PDF]

Transl Breast Cancer Res
Stravodimou A, Voutsadakis IA.
europepmc   +1 more source

TGFβ signaling promotes cell cycle progression and resistance to the CDK4/6 inhibitor palbociclib through SOX4 transcriptional modulation in breast cancer cells. [PDF]

Cell Death Dis
Ali MM, Itoh Y, Badji AMP, Gallant S, Tsirigoti C, Bai Y, Filipek-Górniok B, Miyazawa K, Heldin CH, Moustakas A.   +9 more
europepmc   +1 more source

Continuous Flow Paper Spray Ionization Mass Spectrometry for In-Depth Characterization of Anticancer Drugs in Tissues: Addressing Mass Spectral Complexity. [PDF]

J Am Soc Mass Spectrom
Basuri P, Klinghammer K, Klein O, Volmer DA.   +3 more
europepmc   +1 more source

Genome-wide CRISPR screen identified NEK6 as a determinant of sensitivity to CDK4/6 inhibitor in endometrial cancer. [PDF]

Front Pharmacol
Jian F, Zhu C, Wang Y, Zhou T, Yang C, Feng W.   +5 more
europepmc   +1 more source

Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib. [PDF]

In Vivo
Takada S, Umehara K, Watanabe K.
europepmc   +1 more source